Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A potential baldness cure, possibly PP405, might be available before the release of GTA 6, which is delayed to 2026 or 2027. There is skepticism about the effectiveness and release timeline of PP405.

The conversation is about a user's 5-month progress using topical Minoxidil (5%) and Finasteride (0.1%) twice daily, along with derma stamping, improved Vitamin D levels, and increased protein intake for hair regrowth. The user is considering dutasteride if progress plateaus and uses a sulfate and paraben-free shampoo.

PP405 is progressing to Phase 2b trials, with results expected in late 2025 or early 2026, and potential Phase 3 trials in 2026. Some users experienced side effects from finasteride and are hopeful for PP405 as an alternative treatment.

The conversation discusses the approval of Kintor Pharmaceutical's AR-PROTAC (GT20029) for clinical trials in China for acne and androgenic alopecia. One user expresses optimism about new treatments being developed and seeks clarification on how the new drug works, specifically if it temporarily degrades the AR protein to reduce DHT sensitivity in hair follicles.

Amplifica's progress on Scube3 is unclear, with no recent updates. The conversation also mentions Minoxidil, finasteride, and RU58841 as hair loss treatments.

Sulforaphane, found in broccoli sprouts, promotes hair growth by degrading DHT. Users discuss its potential benefits and joke about unconventional application methods.

Shiseido RCH-01 and Replicel's upcoming trial data release. Users discuss expected release timelines and clarify quarter dates.

A user's 2.5 year transformation of using 0.5mg finasteride and RU58841 to combat hair loss, with the possibility of increasing the RU for further regrowth.

The user has been using minoxidil for 5 months, and added peppermint oil and dermarolling with a 0.5mm roller to their routine 2 months ago. They are happy with the hair regrowth observed since starting the new treatments.

A user is concerned about a change in the formula of Sons topical treatment, which now requires fewer sprays but contains less minoxidil. They question if the change is for convenience or if it's a way to charge the same for less product.

The user reports a stable receding hairline with new hair growth after using 5% minoxidil, 1mg oral finasteride, D-Biotin daily, derma rolling twice a week, and three PRP sessions per month. They plan to update their progress in four months.

The conversation discusses concerns about Scube3's effectiveness and potential cancer link. It questions whether Scube3 can regrow hair and how well it works according to researchers.

The user is happy with their 6-month hair transplant progress of 4600 grafts in Turkey and has been using finasteride for 5 years and minoxidil for 4 years. The donor area is in good condition, potentially allowing for future hair reinforcement.

Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

Switching from 2% liquid minoxidil to 5% foam minoxidil reduced scalp irritation but increased eyebrow flakiness and thinning. The user speculates that propylene glycol in the liquid formulation might have been protecting against seborrheic dermatitis while causing contact dermatitis.

The conversation is about someone's hair regrowth after 1.5 months using natural treatments, specifically a dermaroller and a mix of peppermint, pumpkin seed, and rosemary oils. A reply congratulates them and encourages them to maintain their routine.

PP405 shows promise in hair loss treatment, but stem cell therapy using adipose-derived stem cells and ATP also successfully reversed androgenetic alopecia in mice. Stem cell therapy is costly, and some doubt the effectiveness of PP405 based on press releases.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.

A 45-year-old user shared progress pictures after 4 months of using a topical gel with 2.5% finasteride and 5% minoxidil once daily. The second picture shows significant improvement in hair growth.

A user asks about experiences with Minichek F 5% with Procapil, specifically its drying time. Responses discuss the effectiveness and drying time of the treatment.

A 21-year-old male shares progress pictures showing improvement in hair growth using daily topical minoxidil 5%, microneedling 1.25mm, and 500mg of saw palmetto. He reports new and healthy hair growth, indicating success in managing androgenic alopecia.

The conversation is about a user who experienced significant hair regrowth after using finasteride consistently for five years and recently added a daily minoxidil pill. The user reported no significant side effects and is considering shaving their head again to assess hair density.

The user reported significant hair regrowth and thickening after 5 months using finasteride, minoxidil 5%, biotin, and derma stamping. They experienced some fatigue but no sexual side effects and plan to continue the treatment.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.